Lipegfilgrastim

{{Short description|Pharmaceutical drug}}

{{Use American English|date=July 2020}}

{{Use dmy dates|date=July 2020}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| image =

| width =

| alt =

| caption =

| pronounce =

| tradename = Lonquex

| Drugs.com = {{drugs.com|UK|lonquex}}

| MedlinePlus =

| DailyMedID =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Subcutaneous injection

| class = Immunostimulants, colony-stimulating factors

| ATC_prefix = L03

| ATC_suffix = AA14

| ATC_supplemental =

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2015 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2015 | access-date=10 April 2023}}

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK = POM

| legal_UK_comment = {{cite web | title=Lonquex - Summary of Product Characteristics (SmPC) | website=(emc) | date=3 September 2019 | url=https://www.medicines.org.uk/emc/medicine/28948/SPC/Lonquex/ | access-date=12 July 2020}}

| legal_US =

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism = Saturable proteolytic enzymes (not cytochrome P450 system mediated)

| metabolites =

| onset =

| elimination_half-life = 32–62 hours{{cite journal | vauthors = Hoggatt J, Tate TA, Pelus LM | title = Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia | journal = International Journal of Nanomedicine| volume = 10 | pages = 2647–2652 | date = 2015 | pmid = 25878498 | pmc = 4388090 | doi = 10.2147/IJN.S55796 | doi-access = free }}

| duration_of_action =

| excretion =

| CAS_number = 1117844-87-7

| CAS_supplemental =

| PubChem = 70683024

| IUPHAR_ligand =

| DrugBank = DB13200

| ChemSpiderID =

| UNII = 4AWF0N6QV3

| KEGG = D10242

| ChEBI =

| ChEMBL = 2105765

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = XM-22

| IUPAC_name =

| C=866 | H=1372 | N=226 | O=258 | S=9

| chemical_formula_comment = + PEG

| molecular_weight = 39000

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Lipegfilgrastim, sold under the brand name Lonquex, is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults.{{cite web | title=Lonquex EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex | access-date=13 July 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. It is given by injection under the skin in the abdomen, upper arm or thigh.

The most common side effects include nausea as well as bone and muscle pain.

Lipegfilgrastim is similar to granulocyte colony stimulating factor (G‑CSF), a naturally occurring protein in the body that stimulates the production of white blood cells including neutrophils in the bone marrow. Lipegfilgrastim acts in the same way as G‑CSF, increasing the production of neutrophils and thereby helping to reduce the duration of neutropenia and the occurrence of febrile neutropenia (a sign of infection) in people receiving chemotherapy.

Lipegfilgrastim is a filgrastim biosimilar. In lipegfilgrastim, the filgrastim has been 'pegylated' (attached to polyethylene glycol). This slows down the medicine's removal from the body and allows the medicine to be given less often.

Lipegfilgrastim was authorized for medical use in the European Union in July 2013.